SVSvetlana Yu. Vorotnikova

Svetlana Yu. Vorotnikova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Svetlana Yu. Vorotnikova has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Spontaneous pregnancy in a patient with salt-wasting congenital adrenal hyperplasia due to 21-hydroxilase deficiency: a case report and a literature review

    by I.A. El-Taravi, L.G. Ebanoidze, S.YU. Vorotnikova, M.V. Vorontsova, A.I. Sazonova, N.V. Molashenko

    The present article describes a rare case of pregnancy in a woman with the salt-wasting form of congenital adrenal hyperplasia, 21-hydroxilase deficiency. The patient had been undergoing long-term glucocorticoid and mineralocorticoid therapy. The clinical profile included pronounced hyperandrogenism, a markedly burdened gynecological history, and longstanding infertility. Despite both partners being confirmed heterozygous carriers of pathogenic variants in the CYP21A2 gene, spontaneous conception occurred. The pregnancy was closely monitored and managed by a multidisciplinary team, with individualized adjustment of hormone therapy in accordance with gestational requirements. The antenatal course was uneventful, and at 38 weeks of gestation, an elective cesarean section was performed, resulting in the delivery of a healthy, full-term female neonate. Postnatal genetic testing revealed heterozygous carrier status without phenotypic manifestations of the disease. This clinical case highlights the potential for successful reproductive outcomes in women with severe forms of congenital adrenal hyperplasia, given timely diagnosis, long-term follow-up, and personalized therapeutic strategies. Furthermore, the report underscores the ethical dimensions of reproductive autonomy and parental decision-making in the context of rare autosomal recessive disorders.

  • Open Access

    Growth hormone and fertility: molecular mechanisms and experience of adjuvant therapy in reproductology

    by N. N. Volevodz, M. V. Vorontsova, D. Yu. Nevolnikov, O. R. Grigoryan, S. Y. Vorotnikova, R. K. Mikheev

    Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are pivotal hormones regulating not only postnatal growth, development, aging, and longevity but also female reproductive function. In clinical practice, GH is widely utilized as an ad juvant therapy to enhance various clinical outcomes in assisted reproductive technology (ART). It is aimed at increasing the yield and quality of oocytes and embryos, as well as improving pregnancy and live birth rates both in the general population and among patients with GH deficiency. Over the past three decades, the roles of GH and IGF-1 in regulating female repro duction have garnered increasing attention, becoming a major focus of research in both endocrinology and reproductive medicine.

  • Open Access

    Routing of patients with disorders of carbohydrate metabolism during pregravid preparation and pregnancy (literature review)

    by L. I. Lepeshkina, S. Yu. Vorotnikova, N. G. Mokrysheva, Л. И. Лепешкина, С. Ю. Воротникова, Н. Г. Мокрышева

    Introduction. The increasing incidence of gestational diabetes mellitus and other first-time diagnosed carbohydrate metabolism disorders during pregnancy, along with the associated obstetric and perinatal risks, represents a significant medical and social challenge. The current stage of healthcare development in the Russian Federation is characterized by active modernization of clinical protocols and the regulatory framework governing medical care in the field of endocrinology. However, documents specifying the organization of medical care for pregnant women with gestational diabetes mellitus have not been developed. The purpose of the study : to study and systematize the literature data and regulatory documents reflecting the organization of medical care for pregnant women with impaired carbohydrate metabolism, including to assess the current routing situation of patients with gestational diabetes mellitus. Materials and methods . An analysis was conducted of 106 international (PubMed, Scopus, Medline) and Russian publications (2012–2025), as well as 9 key regulatory documents of the Russian Federation governing care for patients with carbohydrate metabolism disorders. Data systematization was performed using Microsoft Excel. Results. The article examines current regulatory documents reflecting the organization of medical care for pregnant women with carbohydrate metabolism disorders. A detailed analysis of medical care procedures, several orders of the Ministry of Health of Russia, and federal laws was carried out to identify gaps and contradictions in the legal regulation of this group of diseases. In particular, issues of routing patients with established gestational diabetes mellitus are discussed in terms of diagnosis, treatment, delivery, and postpartum management. Detailed data are presented indicating limitations in the existing regulatory framework concerning pregravid preparation of patients with carbohydrate metabolism disorders. The problem caused by untimely consultations with endocrinologists and other specialists is separately characterized. Conclusion. Improving the medical and economic efficiency of managing pregnant women with carbohydrate metabolism disorders and minimizing the risks caused by hyperglycemia during pregnancy, including long-term complications, can only be achieved through the development of regulatory documents on the organization of medical care for this population group and their implementation nationwide.

  • Open Access

    Acromegalic Uteropathy: Specific Uterine Ultrasound Findings in Female Patients

    by Irina Stanoevich, Aurika Asanova, Svetlana Vorotnikova, Andrey Belov, Ekaterina Grezina, Yulia Fedorova, Ugljesa Stanojevic, Larisa Dzeranova, Ekaterina Pigarova, Galina Melnichenko, et al.

    Background/Objectives: Acromegaly is a systemic connective tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess; yet, the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n = 33), healthy controls (n = 45), and adenomyosis without acromegaly (n = 44). Uterine body measurements were obtained by TAUS/TVUS; cervical biometry was performed transvaginally in all cases. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p-values non-significant). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical width, AP thickness, and volume, together with altered U:C indices, whereas cervical length did not differ, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This noninvasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.

  • MEN-1 Management in Clinical Practice: Navigating Complexity Through Multidisciplinary Collaboration

    by L. G. Ebanoidze, Ia. A. El-Taravi, Z. A. Gabaraeva, E. A. Pigarova, D. G. Beltsevich, L. K. Dzeranova, E. G. Przhiyalkovskaya, L. I. Ibragimova, S. Yu. Vorotnikova

    Multiple endocrine neoplasia type 1 (MEN-1) is a rare hereditary disorder characterized by the development of multifocal tumors in endocrine organs. This article presents a clinical case of a female patient with a confirmed MEN1 mutation (c.203delC p.T70fsX118), who exhibited manifestations of various syndrome components over more than 10 years, including parathyroid adenomas, pancreatic neuroendocrine tumors, and a pituitary microprolactinoma. The patient underwent multiple surgical interventions: duodenopancreatectomy, parathyroidectomy with autotransplantation, adrenal resection, and esophageal leiomyoma removal. The study discusses the challenges in diagnosing the primary source of parathyroid hormone secretion, the difficulties in achieving optimal glycemic control due to absolute insulin deficiency following fulminant diabetes mellitus development after total pancreatectomy, as well as aspects of reproductive health and quality of life. This case highlights the importance of a personalized approach and multidisciplinary management in patients with MEN-1 syndrome.

  • A strategy for the long-term postpartum monitoring of women with gestational diabetes: emphasizing secondary prevention

    by L.I. Lepeshkina, S.YU. Vorotnikova, L.K. Dzeranova

    Background. Gestational diabetes mellitus (GDM) is one of the most common complications of pregnancy, affecting, according to 2024 data, approximately 19.7% of pregnancies worldwide. GDM is not merely a transient condition but a marker of a lifelong high cardiometabolic risk for the woman. It is associated with the subsequent development of prediabetes, type 2 diabetes mellitus (T2DM), metabolic syndrome, and cardiovascular diseases. The high recurrence rate of GDM in subsequent pregnancies (up to 84%) and the progressive increase in T2DM risk over time underscore the critical importance of establishing an effective system for secondary prevention, starting from the early postpartum period. However, current clinical practice is often limited to a single examination 4-12 weeks after delivery, which is insufficient for the long-term management of the patient's health. Objective. Using a clinical case example, to demonstrate the significance of long-term postpartum follow-up and the necessity of an active preventive strategy, including pharmacological intervention, in women with a history of GDM to prevent the development of carbohydrate metabolism disorders and cardiometabolic complications. Materials and methods. This paper provides a detailed description of a clinical case of the 33 years old patient with GDM diagnosed at 26-27 weeks of gestation. Standard clinical and laboratory methods were used for pregnancy management and postpartum follow-up: a 75-g oral glucose tolerance test (OGTT), measurement of glycated hemoglobin (HbA1c) levels, self-monitoring of blood glucose, urinalysis with assessment of ketonuria, and fetal ultrasonography. During the postpartum period, an OGTT was used to assess carbohydrate metabolism. Results. During pregnancy, despite diet therapy, the patient exhibited unstable glycemia with episodes of hyperglycemia and ketonuria, which necessitated the initiation of insulin therapy at 32-33 weeks. The pregnancy concluded with a term delivery without complications. An examination 14 months postpartum, following a 13% weight gain from baseline, revealed impaired glucose tolerance (fasting plasma glucose 5.9 mmol/L, 2-hour post-load plasma glucose 8.5 mmol/L). The patient was prescribed a extended-release formulation of metformin at a dose of 500 mg/day in addition to lifestyle modification recommendations. Conclusion. The presented clinical case clearly illustrates that GDM is a predictor of early prediabetes development, even in the absence of abnormalities in the first weeks postpartum. The modern approach to managing patients with a history of GDM should evolve from episodic screening to a system of lifelong dynamic monitoring aimed at the early detection and correction of cardiometabolic risk factors. Lifestyle modification is the cornerstone of prevention; however, it may not be sufficient. The use of metformin in women with prediabetes and a history of GDM is a pathogenetically justified, effective, and safe strategy that not only reduces the risk of T2DM but also has a favorable impact on the lipid profile and cardiovascular health. The active integration of pharmacological prevention into clinical practice is essential for altering the long-term health trajectory of women.

  • Postoperative hypoparathyroidism as a cause of neurologic symptoms mimicking an acute cerebrovascular accident: case report

    by D.K. Erikenova, L.K. Dzeranova, E.A. Pigarova, S.YU. Vorotnikova

    Background. D. Hypoparathyroidism is a disorder caused by decreased secretion of parathyroid hormone and is characterized by hypocalcemia and hyperphosphatemia. Currently, up to 75-80% of hypoparathyroidism cases are postoperative. Transient hypoparathyroidism after thyroidectomy develops in 19-38% of patients, whereas permanent disease occurs in 1-7%. Russian clinical guidelines (2021) report comparable figures. Historically, clinical observations of tetany after thyroid surgery were first described by Ernest Gley in 1891, which contributed to the recognition of the parathyroid glands as an independent endocrine structure [1]. Hypocalcemia may cause a wide spectrum of neurological disturbances, including paresthesia, muscle cramps, tetany, seizures, cognitive impairment, QT interval prolongation, and transient focal neurological symptoms. The clinical presentation may closely resemble acute stroke, leading to inappropriate triage and delayed pathogenetic treatment. According to Goyal A. et al. (Frontiers in Neurology, 2021), up to 12% of episodes of severe hypocalcemia are misinterpreted as stroke. Objective. To present a clinical case of chronic postoperative hypoparathyroidism manifesting as an acute focal neurological deficit initially suspected to be an acute cerebrovascular event, and to emphasize the diagnostic value of assessing calcium–phosphate metabolism and parathyroid hormone levels after thyroid surgery. Materials and methods. We report a clinical case of a 28-year-old woman with Graves’ disease who underwent staged surgical treatment of the thyroid gland (hemithyroidectomy followed by total thyroidectomy), complicated by chronic hypoparathyroidism. A retrospective analysis of clinical manifestations, laboratory parameters (PTH, total and ionized calcium, serum phosphate, and 25(OH) vitamin D), and instrumental investigations was performed, including neuroimaging to exclude acute stroke. The patient’s clinical course and response to acute and maintenance therapy were evaluated. Results. Severe hypocalcemia resulted in acute focal neurological symptoms, prompting emergency hospitalization with suspected stroke. Brain MRI revealed no ischemic lesions. Positive Chvostek and Trousseau signs, together with the rapid regression of neurological deficits after intravenous calcium gluconate administration, supported a metabolic origin of the presentation. Initiation of active vitamin D analogues (alfacalcidol) in combination with oral calcium supplementation led to clinical stabilization and prevention of recurrent episodes. This case highlights the need for routine postoperative monitoring of serum calcium and parathyroid hormone levels after thyroidectomy and for including hypocalcemia in the differential diagnosis of acute neurological conditions to avoid diagnostic errors and ensure timely pathogenetic treatment.

  • Open Access

    Features of vitamin D metabolism and regulation ofcalcium-phosphate homeostasis during pregnancy

    by I.A. Katsobashvili, Е. А. Пигарова, S.YU. Vorotnikova, Е. Е. Бибик, Л. К. Дзеранова, В. А. Иоутси, Л. В. Никанкина

    Background. Gestational diabetes mellitus is a common metabolic complication of pregnancy characterized by impaired glucose tolerance first detected during gestation. Gestational diabetes mellitus affects a substantial proportion of pregnant women worldwide and is associated with an increased risk of adverse maternal and neonatal outcomes. Vitamin D, a secosteroid hormone traditionally known for its role in calcium and phosphorus homeostasis and skeletal health, has attracted growing attention due to its potential involvement in glucose metabolism and insulin regulation. Despite accumulating evidence linking vitamin D status with gestational diabetes mellitus, study results remain inconsistent, particularly regarding the clinical relevance of vitamin D metabolites beyond total 25(OH)D and the dynamic changes in vitamin D metabolism throughout pregnancy. This highlights the need for comprehensive metabolic profiling to better understand how alterations in the vitamin D metabolome during pregnancy are related to calcium-phosphorus balance and the development of gestational diabetes mellitus. Objective. To investigate the features of vitamin D metabolism and calcium-phosphorus homeostasis in pregnant women and their association with gestational diabetes mellitus. Materials and methods. A single-center, observational, prospective, comparative study was conducted. Women with gestational diabetes mellitus (n = 35) underwent longitudinal assessment in the second and third trimesters, including evaluation of multiple components of the vitamin D metabolome using high-performance liquid chromatography coupled with tandem mass spectrometry. For comparison, a control group of conditionally healthy pregnant women (n = 37), matched for age, was formed (p = 0.501). Results. In the second and third trimesters of pregnancy, women with gestational diabetes mellitus showed biochemical parameters of calcium-phosphorus metabolism that remained within the reference range and did not differ significantly from the control group. Concentrations of 25(OH)D3 and other vitamin D metabolites in women with gestational diabetes mellitus were largely comparable to controls, with a statistically significant reduction observed only for 24,25(OH)2D3 in the second trimester. No differences were found in the ratios of vitamin D metabolites reflecting the activity of key metabolic enzymes. During pregnancy, women with gestational diabetes mellitus demonstrated a decrease in albumin levels with stable albumin-corrected calcium, as well as a trend toward increased concentrations of 3-epi-25(OH)D3 and 24,25(OH)2D3 by the third trimester. Conclusion. Pregnant women with gestational diabetes mellitus exhibit lower serum 25(OH)D3 concentrations in the second trimester and reduced levels of the metabolites 1,25(OH)2D3 and 24,25(OH)2D3 in the third trimester compared with the control group. Ratios between vitamin D metabolites reflecting the activity of key enzymes involved in vitamin D metabolism remain stable, indicating preserved enzymatic regulation. The observed differences are most likely attributable to baseline vitamin D status rather than to disturbances in enzymatic metabolism. Thus, the results of the present study, together with an analysis of current clinical guidelines, support the rationale for continuous vitamin D supplementation from the first trimester of pregnancy until delivery. These findings highlight the importance of early (preconception) assessment of 25(OH)D3 status and timely correction of its levels to optimize the metabolic profile and reduce the risk of gestational diabetes mellitus during pregnancy.

  • Open Access

    Acromegalic Uteropathy: Specific Uterine Ultrasound Findings in Female Patients

    by Irina Stanoevich, Aurika Asanova, Svetlana Vorotnikova, Andrey Belov, Ekaterina Grezina, Yulia Fedorova, Ugljesa Stanojevic, Larisa Dzeranova, Ekaterina Pigarova, Galina Melnichenko, et al.

    Background/Objectives: Acromegaly is a systemic connective-tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess, yet the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n=33), healthy controls (n=45), and adenomyosis without acromegaly (n=44). Uterine body and cervical length, width, and anteroposterior (AP) dimensions were measured transvaginally/transabdominally. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p>0.1). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical dimensions and altered U:C indices, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This non-invasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.

  • Open Access

    «Gestational Hyperandrogenism»: Clarifying Terminology and Practical Management

    by L. I. Lepeshkina, S. Y. Vorotnikova, G. A. Mel’nIchenko

    This review examines the terminological ambiguity surrounding the concept of «gestational hyperandrogenism» in domestic literature and clinical practice. An increase in androgen levels during pregnancy, driven by hormonal adaptation, involvement of the fetoplacental complex, and altered synthesis of sex hormone-binding globulins in the liver, represents a physiological norm. Consequently, patient management in most cases is limited to active monitoring and does not require medical intervention. A key emphasis is placed on distinguishing between pregestational hyperandrogenism and true gestational hyperandrogenism — a rare pathological condition that first manifests during pregnancy due to causes such as luteoma, theca-lutein cysts, or placental aromatase deficiency, all of which typically resolve spontaneously after delivery. The review outlines a systematic approach to the differential diagnosis of these conditions, which is crucial for determining further management strategy and preventing inappropriate treatment. Incorrect interpretation of laboratory findings and overdiagnosis often lead to the erroneous prescription of glucocorticoids to pregnant women, posing potential risks. The article delineates patient management strategies based on identifying the source of hyperandrogenism and assessing the risk of fetal virilization, with an emphasis on dynamic monitoring. Particular attention is paid to the need for topical diagnosis using imaging techniques, as well as the dynamic assessment of androgen status postpartum. Treatment options for true gestational hyperandrogenism are limited, whereas glucocorticoid therapy is justified only in cases of pregestational hyperandrogenism due to congenital adrenal hyperplasia.